SAN FRANCISCO--(BUSINESS WIRE)--Encellin, a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing ...
LAS VEGAS, Dec. 16, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes ...
In a recent article in Scientific Reports, researchers examined the use of single-layer graphene oxide (slGO) nanosheets to enhance the proliferation and osteogenic differentiation of human bone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results